GOVERNMENT

ARMONK, NY -- IBM (NYSE: IBM) and Accelrys, Inc., a wholly owned subsidiary of Pharmacopeia, Inc. (NASDAQ: PCOP), today announced a global strategic alliance to enhance drug research and development (R&D) operations by creating a collaborative information technology environment for chemists and biologists to develop new drugs faster, more efficiently, and at lower costs. Through the agreement, Accelrys, one of the world's leading software developers in life sciences, will become a premier partner in IBM's PartnerWorld for Developers Program, a status reserved for top-tier strategic alliance partners. IBM and Accelrys will team up, with each company contributing key technologies, to help pharmaceutical and biotechnology companies and medical research centers improve their R&D operations and shorten the development cycle for new drugs. "This alliance represents one of the most significant and influential relationships for IBM in life sciences," said Dr. Caroline Kovac, general manager, IBM Life Sciences. "IBM and Accelrys share the common goal of developing innovative technology solutions that will benefit the life sciences community and accelerate drug discovery and development. Our relationship will leverage IBM's cutting-edge supercomputing technologies and Accelrys' broad software expertise to drive the new levels of efficiency in pharmaceutical R&D." Alliance Highlights Under the terms of the four-year alliance, IBM becomes Accelrys' preferred information technology and services partner for life sciences. IBM's eServer systems will be Accelrys' server family of choice for life sciences applications. Through its collaboration with IBM, Accelrys will accelerate the delivery of its Discovery Studio platform, which promises to be the industry's first technology platform to fully support the entire drug discovery process. Discovery Studio is a set of Accelrys technologies that will offer broad access to key life sciences applications, while enabling effective capture and reuse of critical scientific information and knowledge, whether generated by Accelrys' portfolio of software products, in-house or by third parties. "The drug industry is asking for a consolidated, integrated platform for sharing data and knowledge," said Dr. Michael Stapleton, chief operating officer and executive vice president of Accelrys. "We chose IBM as our technology partner because of their commitment to the market we serve and their strength in high-performance computing, software, and services that align with our goals. Through IBM's and Accelrys' complementary technologies, we can help customers increase the productivity of their drug development efforts and get more successful drug candidates through the development cycle faster." Other key elements of the alliance include: -- Accelrys will enable its software applications to run optimally on IBM eServer systems for UNIX, Windows NT and Linux. Accelrys applications, which support R&D processes ranging from early isolation of target genes and proteins associated with particular diseases, through synthesizing chemical compounds that will work on these targets, to pre-clinical testing and drug delivery, are used by virtually every major pharmaceutical and most major biotechnology and chemical companies. -- Accelrys becomes a premier member of IBM's PartnerWorld for Developers Program (www.developer.ibm.com), which offers business partners a wide range of sales, education, training, and technical support programs. This worldwide program is designed to help software developers reach broader markets faster and lower their costs of doing business. -- Accelrys will use IBM eServer p690 (code named "Regatta") systems running AIX, IBM eServer xSeries systems running Linux and Windows NT, and the IBM eServer Cluster 1300 Linux system for software development, testing and knowledge management applications. -- Accelrys will combine IBM DiscoveryLink data integration technology with the new Discovery Studio platform. -- IBM and Accelrys will jointly market Discovery Studio offerings for IBM platforms and middleware. -- IBM and Accelrys will provide a range of joint consulting and implementation services for deploying solutions that combine mutual technologies. "This announcement is the latest example of how the emerging bioscience sector is a major catalyst for growth in high-performance technical computing, in the same way that the application of simulation and modeling was to defense, manufacturing and petroleum in years past," said Debra Goldfarb, group vice president, International Data Corporation. "The IBM-Accelrys alliance should be welcome news in an industry feeling tremendous pressure to innovate, and could result in impressive market share gains for both companies." According to the TOP500 Supercomputer list (www.top500.org), IBM systems account for 160 of the world's 500 most powerful high-performance computers and half of the top 10 more powerful machines -- more than any other vendor. The list was published in November 2001 by supercomputing experts Jack Dongarra from the University of Tennessee and Erich Strohmaier and Hans Meuer of the University of Mannheim (Germany). "Life science IT solutions will have dramatic growth in the next several years," said Dorman Followwill, Vice President, HealthCare, Frost & Sullivan. "This reflects the historic convergence of IT and biology, where the limits of biology now equal the limits of computing. It is difficult to overstate the future role of IT in modernizing the drug discovery and development process through high-performance computing, services and software for translating reams of genomic/proteomic data into clinically useful information. IBM and Accelrys are well positioned to lead the way in this space." For additional information visit www.ibm.com/solutions/lifesciences